Onxeo Receives EPO Intent-to-Grant Notice for New Patent Protecting AsiDNA™ in Combination with Any PARP Inhibitor
PARIS--(BUSINESS WIRE)--Dec 18, 2018--Regulatory News:
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced having been notified by the European Patent Office (EPO) of its intent to grant the Company a new patent (EP3325623) covering the combination of AsiDNA™, Onxeo’s first-in-class agonist of the DNA Damage Response (DDR) , with any PARP inhibitor (PARPi), in all countries of the European Union (EU).
This new patent protects the intellectual property of Onxeo relating to combined preparations comprising conjugated nucleic acid molecules, including its lead product candidate AsiDNA™ and a PARP inhibitor, as well as the use of the combined preparations for the treatment of cancer. Under the patent, AsiDNA™ and the PARP inhibitor may be present in one combined dosage form, or as part of separate dosage forms for sequential administration of the respective drugs. This European patent has a term expiring in mid-2036.
Onxeo has conducted extensive preclinical studies of AsiDNA™ in combination with various PARPi. These studies show that the combination has a strong synergistic anti-tumor activity in solid tumors, regardless of the genetic mutation status of the tumor. This synergy appears to be a class effect with all PARPi. Combination with AsiDNA™ could therefore represent an opportunity to expand PARPi indications to HR proficient tumors, which account for approximately 70% of tumors.
“This patent covering the combination of AsiDNA™ with any PARP inhibitor further reinforces our extensive patent portfolio, which is a key component of the value of AsiDNA™. Our strong intellectual property position is an integral part of the Company’s business model, which aims to progress disruptive compounds up to the most valuable clinical inflexion points and then to partner or license them, ” said Judith Greciet, Chief Executive Officer of Onxeo.
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
Onxeo is developing AsiDNA™, a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a unique decoy & agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the unique properties of AsiDNA™, notably its ability to oppose and even reverse tumor resistance to PARP inhibitors regardless of the genetic mutation status, and its strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. AsiDNA™ is currently being evaluated for systemic (IV) administration in advanced solid tumors in the DRIIV-1 phase I study (DNA Repair Inhibitor administered IntraVenously).
AsiDNA™ is the first compound generated from platON™, the Company’s proprietary chemistry platform of decoy oligonucleotides dedicated to generate new innovative leads and broaden Onxeo’s pipeline.
Onxeo’s portfolio also includes belinostat, an HDAC inhibitor (epigenetics). Belinostat is already conditionally FDA-approved in the US as a 2 nd line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo’s partner, Spectrum Pharmaceuticals, under the name Beleodaq® (belinostat IV form).
Forward looking statements
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 126.96.36.199 “Risk Factors” (” Facteurs de Risque ”) of the 2016 reference document filed with the Autorité des marchés financiers on April 24, 2017 under number D.17-0423, which is available on the Autorité des marchés financiers website ( www.amf-france.org ) or on the Company’s website ( www.onxeo.com ).
View source version on businesswire.com:https://www.businesswire.com/news/home/20181218005791/en/
+33 1 45 58 76 00
+33 6 64 18 99 59
Investor Relations / Strategic Communication
Dušan Orešanský / Emmanuel Huynh
+33 1 44 71 94 92
Investor Relations US
+1 212 9152578
KEYWORD: EUROPE FRANCE
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS ONCOLOGY PHARMACEUTICAL
SOURCE: Onxeo S.A.
Copyright Business Wire 2018.
PUB: 12/18/2018 02:30 PM/DISC: 12/18/2018 02:30 PM